Search

Your search keyword '"Colaneri, M."' showing total 3 results
Start Over Author "Colaneri, M." Journal cardiology in the young
3 results on '"Colaneri, M."'

1. Everolimus-induced near-resolution of giant cardiac rhabdomyomas and large renal angiomyolipoma in a newborn with tuberous sclerosis complex

Author

Andrea Quarti, Massimo Colaneri, Marco Pozzi, Colaneri M., Quarti A., and Pozzi M.

Subjects
Male, Pathology, medicine.medical_specialty, Angiomyolipoma, Antineoplastic Agents, tuberous sclerosis complex, 030204 cardiovascular system & hematology, Rhabdomyoma, Heart Neoplasms, Antineoplastic Agent, Lesion, 03 medical and health sciences, Tuberous sclerosis, Heart Neoplasm, 0302 clinical medicine, Tuberous Sclerosis, 030225 pediatrics, medicine, Humans, Everolimus, Cardiac rhabdomyoma, medicine.diagnostic_test, business.industry, everolimu, Infant, Newborn, Infant, Kidney Neoplasm, Magnetic resonance imaging, General Medicine, medicine.disease, Magnetic Resonance Imaging, Kidney Neoplasms, Treatment Outcome, Echocardiography, Pediatrics, Perinatology and Child Health, medicine.symptom, Cardiology and Cardiovascular Medicine, business, Human, medicine.drug, Renal angiomyolipoma
Abstract

We report a case of a newborn, affected by tuberous sclerosis complex, with a prenatally diagnosed giant cardiac rhabdomyoma associated with a large renal angiomyolipoma presenting as a duct-depending lesion not treatable by surgery. After receiving everolimus, a mammalian target of rapamycin inhibitor, we observed a rapid, significant, and durable reduction of both lesions without remarkable side effects.

Published
2016
Full Text
View/download PDF

2. Patent ductus arteriosus in preterm infants born before 30 weeks' gestation: high rate of spontaneous closure after hospital discharge.

Author

Romagnoli V, Pedini A, Santoni M, Scutti G, Colaneri M, Pozzi M, Cogo PE, and Carnielli VP

Subjects
Administration, Intravenous, Cyclooxygenase Inhibitors therapeutic use, Female, Follow-Up Studies, Gestational Age, Humans, Ibuprofen therapeutic use, Indomethacin therapeutic use, Infant, Infant, Newborn, Italy epidemiology, Ligation, Male, Patient Discharge, Remission Induction, Retrospective Studies, Ductus Arteriosus, Patent therapy, Infant, Extremely Low Birth Weight, Infant, Extremely Premature, Remission, Spontaneous
Abstract

AimThe aim of this study was to determine the spontaneous closure rate of patent ductus arteriosus at a 2-year follow-up, following failed medical therapy and beyond initial hospital discharge, and to evaluate in-hospital spontaneous or pharmacological closure rates.Materials and methodsA retrospective evaluation was conducted in a cohort of preterm infants admitted to the Neonatal ICU of Ancona between January, 2004 and June, 2013. Inclusion criteria were gestational age between 24+0 and 29+6 weeks or birth weight 1.5 mm, a left atrium-to-aorta ratio >1.4, and/or reversal of end-diastolic flow in the aorta >30% of the anterograde. First-line treatment was intravenous ibuprofen. Intravenous indomethacin was used if ibuprofen failed. Surgical ligation was considered in haemodynamically significant patent ductus arteriosus after medical treatment., Results: A total of 593 infants met the inclusion criteria, and patent ductus arteriosus was diagnosed in 317 (53.4%). Among them, 283 (89.3%) infants had haemodynamically significant patent ductus arteriosus, with pharmacological closure achieved in 228 (80.6%) infants and surgical ligation performed in 20 (7.1%). Follow-up at 24 months was available for 39 (81.3%) of 48 infants with patent ductus arteriosus at the hospital discharge: 36 (92.3%) underwent spontaneous closure, two (5.1%) underwent surgical ligation, and one (2.6%) had a patent ductus arteriosus.DiscussionA significant number of patent ductus arteriosus that fail pharmacological closure undergo spontaneous closure by the age of 2 years. This information should be taken into account when considering surgery or additional attempts of pharmacological closure.

Published
2018
Full Text
View/download PDF

3. Everolimus-induced near-resolution of giant cardiac rhabdomyomas and large renal angiomyolipoma in a newborn with tuberous sclerosis complex.

Author

Colaneri M, Quarti A, and Pozzi M

Subjects
Angiomyolipoma drug therapy, Echocardiography, Heart Neoplasms drug therapy, Humans, Infant, Infant, Newborn, Kidney Neoplasms drug therapy, Magnetic Resonance Imaging, Male, Rhabdomyoma drug therapy, Treatment Outcome, Angiomyolipoma diagnostic imaging, Antineoplastic Agents administration & dosage, Everolimus administration & dosage, Heart Neoplasms diagnostic imaging, Rhabdomyoma diagnostic imaging, Tuberous Sclerosis complications
Abstract

We report a case of a newborn, affected by tuberous sclerosis complex, with a prenatally diagnosed giant cardiac rhabdomyoma associated with a large renal angiomyolipoma presenting as a duct-depending lesion not treatable by surgery. After receiving everolimus, a mammalian target of rapamycin inhibitor, we observed a rapid, significant, and durable reduction of both lesions without remarkable side effects.

Published
2016
Full Text
View/download PDF

Catalog

Books, media, physical & digital resources
See catalog results